Vasopressin as a target for antidepressant development: an assessment of the available evidence.
AffiliationDepartment of Psychiatry, Cork University Hospital, Cork, Ireland., firstname.lastname@example.org
MeSHAdrenocorticotropic Hormone/cerebrospinal fluid/drug effects/metabolism
Antidepressive Agents/*pharmacology/*therapeutic use
Corticotropin-Releasing Hormone/cerebrospinal fluid/drug effects/metabolism
Depressive Disorder, Major/cerebrospinal fluid/*drug therapy/physiopathology
Hypothalamo-Hypophyseal System/drug effects/metabolism/physiopathology
Pituitary-Adrenal System/drug effects/metabolism/physiopathology
Receptors, Vasopressin/drug effects
Vasopressins/cerebrospinal fluid/*drug effects/*metabolism
MetadataShow full item record
CitationJ Affect Disord. 2002 Nov;72(2):113-24.
JournalJournal of affective disorders
AbstractHyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the key biological abnormalities described in major depressive disorder, occurring in 30-50% of depressed subjects. Corticotropin-releasing hormone (CRH) and vasopressin (AVP) are the main regulators of this stress system, with the two neuropeptides acting synergistically in bringing about adrenocorticotropin (ACTH) release from the anterior pituitary and cortisol from the adrenal gland. Based on the demonstration of elevated cerebrospinal fluid levels of CRH in depressives, and other evidence, it has been postulated that excess CRH and the resultant increased HPA forward drive form the basis of neuroendocrine dysregulation in depression. However, there is an accumulating body of evidence to support a significant role for AVP in the regulation of pituitary-adrenal activity in health and also in depressive disorder. This review, based on a Medline search from 1980 to 2001, focuses on the functional neuroanatomy, receptor pharmacology, VP synergism with CRH, and the data from clinical and pre-clinical studies that support an important role for AVP in the pathophysiology of major depression. We suggest that future antidepressants may target the vasopressinergic system.
- The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants.
- Authors: Stewart LQ, Roper JA, Young WS 3rd, O'Carroll AM, Lolait SJ
- Issue date: 2008 May
- Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.
- Authors: Scott LV, Dinan TG
- Issue date: 1998
- An investigation of hypothalamic-pituitary-adrenal axis hyperactivity in anorexia nervosa: the role of CRH and AVP.
- Authors: Connan F, Lightman SL, Landau S, Wheeler M, Treasure J, Campbell IC
- Issue date: 2007 Jan-Feb
- Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects.
- Authors: Rubin RT, O'Toole SM, Rhodes ME, Sekula LK, Czambel RK
- Issue date: 1999 Dec 13
- Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.
- Authors: Poretti MB, Sawant RS, Rask-Andersen M, de Cuneo MF, Schiöth HB, Perez MF, Carlini VP
- Issue date: 2016 Mar